当前位置: X-MOL 学术Antivir. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre study.
Antiviral Therapy ( IF 1.3 ) Pub Date : 2017-6-22 , DOI: 10.3851/imp3179
Kessarin Thanapirom 1, 2 , Sirinporn Suksawatamnuay 1, 2 , Wattana Sukeepaisarnjaroen 3 , Sombat Treeprasertsuk 1, 2 , Tawesak Tanwandee 4 , Phunchai Charatcharoenwitthaya 4 , Satawat Thongsawat 5 , Apinya Leerapun 5 , Teerha Piratvisuth 6 , Rattana Boonsirichan 7 , Chalermrat Bunchorntavakul 8 , Chaowalit Pattanasirigool 9 , Bubpha Pornthisarn 10 , Supoj Tuntipanichteerakul 11 , Ekawee Sripariwuth 12 , Woramon Jeamsripong 13 , Theeranun Sanpajit 14 , Yong Poovorawan 15 , Piyawat Komolmit 1, 2
Affiliation  

Sodium taurocholate co-transporting polypeptide (NTCP) is a cell receptor for HBV. The S267F variant on the NTCP gene is inversely associated with the chronicity of HBV infection, progression to cirrhosis and hepatocellular carcinoma in East Asian populations. The aim of this study was to determine whether the S267F variant was associated with response to pegylated interferon (PEG-IFN) in patients with chronic HBV infection.

中文翻译:

慢性乙型肝炎患者NTCP基因上S267F变体与聚乙二醇干扰素治疗反应的关联:一项多中心研究。

牛磺胆酸钠共转运多肽(NTCP)是HBV的细胞受体。NTCP基因上的S267F变体与HBV感染的慢性,在东亚人群中进展为肝硬化和肝细胞癌呈负相关。这项研究的目的是确定在慢性HBV感染患者中,S267F变体是否与对聚乙二醇化干扰素(PEG-IFN)的反应有关。
更新日期:2020-08-21
down
wechat
bug